Becton, Dickinson and Company (BDX) Holdings Lifted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 5.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 482,864 shares of the medical instruments supplier’s stock after acquiring an additional 23,400 shares during the period. Dimensional Fund Advisors LP owned about 0.23% of Becton, Dickinson and worth $94,205,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the period. Vanguard Group Inc. increased its stake in Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after buying an additional 1,353,780 shares during the period. Parametric Portfolio Associates LLC increased its stake in Becton, Dickinson and by 216.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 1,320,259 shares of the medical instruments supplier’s stock worth $257,596,000 after buying an additional 902,761 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its stake in Becton, Dickinson and by 49,944.3% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 863,264 shares of the medical instruments supplier’s stock worth $168,431,000 after buying an additional 861,539 shares during the period. Finally, Findlay Park Partners LLP increased its position in shares of Becton, Dickinson and by 85.1% in the 2nd quarter. Findlay Park Partners LLP now owns 1,725,000 shares of the medical instruments supplier’s stock valued at $336,565,000 after purchasing an additional 792,942 shares during the last quarter. 86.83% of the stock is currently owned by institutional investors and hedge funds.



BDX has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Royal Bank Of Canada reissued a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a research report on Wednesday. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their target price for the company from $210.00 to $180.00 in a report on Friday, June 30th. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Finally, Wells Fargo & Company assumed coverage on shares of Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Becton, Dickinson and has an average rating of “Buy” and an average price target of $205.14.

ILLEGAL ACTIVITY WARNING: “Becton, Dickinson and Company (BDX) Holdings Lifted by Dimensional Fund Advisors LP” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/dimensional-fund-advisors-lp-has-94-21-million-stake-in-becton-dickinson-and-co-bdx.html.

Becton, Dickinson and Company (BDX) traded up 0.12% during midday trading on Friday, hitting $210.10. 1,571,834 shares of the company’s stock traded hands. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $214.72. The company has a 50 day moving average of $199.26 and a 200-day moving average of $194.48. The company has a market capitalization of $47.81 billion, a PE ratio of 60.85 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.35 EPS. Equities research analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

In other Becton, Dickinson and news, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the sale, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last three months, insiders sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply